scispace - formally typeset
Open AccessJournal ArticleDOI

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia

TLDR
A quantitative immunoblot experiment supports the presence of extensive molecular abnormalities to PSD95 and several of its associated proteins in the CA1 region in schizophrenia, offering a small but significant step toward understanding how protein levels in the PSD are altered in the schizophrenia brain, and their relevance to overall hippocampal and cognitive dysfunction in the illness.
Abstract
Alterations of postsynaptic density (PSD)95-complex proteins in schizophrenia ostensibly induce deficits in synaptic plasticity, the molecular process underlying cognitive functions. Although some PSD95-complex proteins have been previously examined in the hippocampus in schizophrenia, the status of other equally important molecules is unclear. This is especially true in the cornu ammonis (CA)1 hippocampal subfield, a region that is critically involved in the pathophysiology of the illness. We thus performed a quantitative immunoblot experiment to examine PSD95 and several of its associated proteins in the CA1 region, using post mortem brain samples derived from schizophrenia subjects with age-, sex-, and post mortem interval-matched controls (n=20/group). Our results indicate a substantial reduction in PSD95 protein expression (-61.8%). Further analysis showed additional alterations to the scaffold protein Homer1 (Homer1a: +42.9%, Homer1b/c: -24.6%), with a twofold reduction in the ratio of Homer1b/c:Homer1a isoforms (P=0.011). Metabotropic glutamate receptor 1 (mGluR1) protein levels were significantly reduced (-32.7%), and Preso, a protein that supports interactions between Homer1 or PSD95 with mGluR1, was elevated (+83.3%). Significant reduction in synaptophysin (-27.8%) was also detected, which is a validated marker of synaptic density. These findings support the presence of extensive molecular abnormalities to PSD95 and several of its associated proteins in the CA1 region in schizophrenia, offering a small but significant step toward understanding how proteins in the PSD are altered in the schizophrenia brain, and their relevance to overall hippocampal and cognitive dysfunction in the illness.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures.

TL;DR: Findings of moderate–large reductions in synaptophysin in hippocampus and frontal cortical regions, and a tendency for reductions in other pre- and postsynaptic proteins in the hippocampus are consistent with models that implicate synaptic loss in schizophrenia, but they also identify potential differences between regions and proteins, suggesting synaptic loss is not uniform in nature or extent.
Journal ArticleDOI

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats.

TL;DR: It is shown for the first time in vivo that levels of the synaptic marker protein SV2A are reduced in schizophrenia and unaffected by antipsychotic treatment in a rat model, indicating that there are lower synaptic terminal protein levels in schizophrenia in vivo and that antipsychotics exposure is unlikely to account for them.
Journal ArticleDOI

Synapse Pathology in Schizophrenia : A Meta-analysis of Postsynaptic Elements in Postmortem Brain Studies

TL;DR: This meta-analysis shows a region-specific decrease in the density of postsynaptic elements in SCZ, which provides an important cellular hallmark for future preclinical and neuropathological research in order to increase the understanding of brain dysconnectivity inSCZ.
Journal ArticleDOI

Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development.

TL;DR: A state-of-the-art review of new PET tracers for CNS targets, focusing on developments in the last 5 years for targets recently available for in-human imaging, shows that multiple new tracers have been developed for proteinopathy targets, particularly tau, as well as the purinoceptor P2X7, phosphodiesterase enzyme PDE10A, and synaptic vesicle glycoprotein 2A (SV2A), amongst others.
Journal ArticleDOI

Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system.

TL;DR: MGlu3 receptors, which are traditionally linked to the control of neurotransmitter release, support mGlu5 receptor signaling in neurons and largely contribute to the robust mGLU5 receptor‐mediated polyphosphoinositide hydrolysis in the early postnatal life.
References
More filters
Journal ArticleDOI

PDZ domain proteins of synapses

TL;DR: PDZ domains are protein-interaction domains that are often found in multi-domain scaffolding proteins that function in the dynamic trafficking of synaptic proteins by assembling cargo complexes for transport by molecular motors.
Journal ArticleDOI

Enriched environments, experience-dependent plasticity and disorders of the nervous system.

TL;DR: Findings on the environmental modulators of pathogenesis and gene–environment interactions in CNS disorders, and their therapeutic implications, are reviewed.
Journal ArticleDOI

Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins

TL;DR: It is reported that Shank proteins also bind to Homer, and Shank may cross-link Homer and PSD-95 complexes in the PSD and play a role in the signaling mechanisms of both mGluRs and NMDA receptors.
Journal ArticleDOI

Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia

TL;DR: A circuit-based framework for understanding gene and neurotransmitter interactions in schizophrenia is developed and Nicotine enhances the output of interneurons, and might thereby contribute to its therapeutic effect in schizophrenia.
Journal ArticleDOI

Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

TL;DR: In this article, the authors used array tomography (AT) to quantify synapse loss in Alzheimer's disease and found that senile plaques are surrounded by a halo of oligomeric forms of amyloid beta.
Related Papers (5)